Covidien Ventures Into Capsule-Based Endoscopy With Given Imaging Acquisition
This article was originally published in The Gray Sheet
Executive Summary
The $860 million purchase agreement will give Covidien the dominant capsule endoscopy platform on the market as the company hopes for FDA approval this year of PillCam COLON 2 as a less invasive alternative for patients who are unable to undergo a colonoscopy.
You may also be interested in...
News Briefs: PillCam Colon Clearance; CGM For Pediatrics; SGR Reform Bill
Given Imaging, soon to be part of Covidien, gained clearance for PillCam Colon capsule endoscopy device. FDA approves its first continuous glucose monitoring system for kids. Congress makes progress in the sustainable growth rate formula bill. More news.
Reimbursement Briefs: PillCam Reimbursement In Japan; 3-D Mammo Code Withdrawn; CMS Data Sharing
Japan will reimburse PillCam COLON. 3-D mammography CPT code application withdrawn from AMA CPT Editorial Panel meeting. CMS unveils new virtual research data-sharing tool.
Capsule Endoscopy: Poised For Growth
The market for capsule endoscopy is one of the fastest growing segments in the multibillion-dollar gastrointestinal endoscopy market. The market opportunity is vast and highly underpenetrated, and an increasing number of competitors, new product innovations, and expanding indications for the technology are positioning capsule endoscopy as a market poised for growth – particularly if the technology is proven and FDA cleared for colon cancer indications.